<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900340</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 25/11</org_study_id>
    <nct_id>NCT01900340</nct_id>
  </id_info>
  <brief_title>Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans</brief_title>
  <official_title>Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to further establish a physiological role for GLP-1 as an endogenous satiety
      signal by examining the effect of the specific GLP-1 receptor antagonist exendin (9-39) on
      appetite and food intake in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Understanding the exact mechanisms by which GLP-1 inhibits eating can be crucial in order to
      convert its anorectic action into useful, safe and effective drugs. So far, it is however not
      clear to what extent GLP-1 is a hormonal regulator of eating or whether the observed effects
      are rather a pharmacological phenomenon. By applying classical algorithms from endocrinology
      several criteria must be fulfilled before a hormone can be considered an endogenous
      physiological satiety signal. One is that exogenous administration of a selective antagonist
      should prevent the eating-inhibitory effect of GLP-1. At present, cholecystokinin (CCK) is
      the only peptide in humans identified to fit these criteria. For intestinal GLP-1, it has not
      been investigated whether a specific GLP-1 receptor antagonist can block the
      eating-inhibitory effect in humans. The availability of a specific GLP-1 receptor antagonist,
      exendin (9-39), now makes it possible to further investigate this pathway. Exendin (9-39), is
      a powerful tool available for human use to characterize of endogenous GLP-1 as a
      physiological regulator of different biological functions. The molecule has been used to
      document that endogenous GLP-1 is an important incretin hormone and a regulator of
      antro-pyloro-duodenal motility. The role of endogenous GLP-1 in regulating food intake and
      appetite has, however, not been investigated before.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of exendin(9-39)on total calorie intake</measure>
    <time_frame>60 min test meal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of exendin(9-39) on total fluid intake</measure>
    <time_frame>60 min test meal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of exendin(9-39)on meal duration during an ad libitum test meal.</measure>
    <time_frame>60 min test meal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of exendin(9-39)on plasma concentration of glucose</measure>
    <time_frame>4 hours blood sampling</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of exendin(9-39)on plasma concentration of insulin.</measure>
    <time_frame>4 hours blood sampling</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of exendin(9-39)on plasma concentration of glucagon.</measure>
    <time_frame>4 hours blood sampling</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of exendin(9-39)on plasma concentration of GLP-1.</measure>
    <time_frame>4 hours blood sampling</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of exendin(9-39)on plasma concentration of peptide tyrosine tyrosine (PYY).</measure>
    <time_frame>4 hours blood sampling</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of exendin(9-39)on plasma concentration of CCK.</measure>
    <time_frame>4 hours blood sampling</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of exendin(9-39)on plasma concentration of ghrelin.</measure>
    <time_frame>4 hours blood sampling</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Appetite and General Nutritional Disorders</condition>
  <arm_group>
    <arm_group_label>iv saline, intraduodenal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous infusion of saline plus intraduodenal administration of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV exendin(9-39) plus intraduodenal (ID) saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous infusion of exendin(9-39) plus intraduodenal administration of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV saline, intraduodenal nutrient</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous infusion of saline plus intraduodenal administration of nutrient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin(9-39) plus ID nutrient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous saline infusion and intraduodenal administration of saline via feeding tube</description>
    <arm_group_label>iv saline, intraduodenal saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin 9-39</intervention_name>
    <description>IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube</description>
    <arm_group_label>IV exendin(9-39) plus intraduodenal (ID) saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>IV saline infusion and intraduodenal administration of nutrients</description>
    <arm_group_label>IV saline, intraduodenal nutrient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin(9-39) plus ID nutrient</intervention_name>
    <description>Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration</description>
    <arm_group_label>Exendin(9-39) plus ID nutrient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subject with a BMI of 19-25 m2/kg

          2. Stable body weight for at least three months

          3. Normal eating habits

          4. Age between 18 and 45 years

          5. Sufficient understanding of the German language

          6. Subjects understand the procedures and the risks associated with the study

          7. Participants must be willing to adhere to the protocol and sign the consent form

        Exclusion Criteria:

          1. Participation in another clinical trial (currently or within the last 30 days)

          2. Smoking

          3. Substance abuse

          4. Regular intake of medications (except for oral contraceptives)

          5. Chronic or acute medical condition including clinically relevant abnormality in
             physical exam or laboratory values

          6. History of gastrointestinal disorders

          7. Food allergies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Phase 1 Research Unit, Basel Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel, Phase 1 Research Unit</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2013</study_first_posted>
  <last_update_submitted>July 11, 2013</last_update_submitted>
  <last_update_submitted_qc>July 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>satiation peptides</keyword>
  <keyword>food intake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

